Skip to content

Effectiveness of a care plan for cancer survivors

Efficacy of the Treatment Summary and Survivorship Care Plan (TSSCP-S): experimental study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2m7qkjy
Enrollment
Unknown
Registered
2022-04-19
Start date
2021-03-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Interventions

ntervention group: 100 breast cancer survivors, diagnosed at all stages, who had the end of treatment (except endocrine therapy) and have their first follow-up appointment, will be followed up for a p
E05.318.308.980

Sponsors

Universidade Federal de São Paulo
Lead Sponsor
Fundação Antônio Prudente
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18; breast cancer patients; women; tumor at all stages; submitted to clinical therapies with chemotherapy, surgical and radiotherapy; who have completed the treatment (except endocrine therapy)

Exclusion criteria

Exclusion criteria: Patients who have not undergone surgical procedures for the treatment of breast cancer; patients with psychiatric disorders attested to in medical records, which makes educational practice unfeasible

Design outcomes

Primary

MeasureTime frame
To evaluate the quality of life, level of distress and self-efficacy of women who survived breast cancer, submitted to the educational program, using the Treatment Summary and Survivorship Care Plan, translated and validated into Portuguese, through a methodological study and randomized experimental; and presentation of quantitative variables, considering the summary measures of position and dispersion, such as mean, median, standard deviation, minimum and maximum values, absolute and relative frequencies (%). It is expected as an outcome the improvement of quality of life, level of distress and self-efficacy in the period of three, six and nine months after the end of the last clinical treatment (except endocrine therapy), surgical and radiotherapy, verified through Fisher's exact test and Pearson's correlation coefficient, based on the observation of a variation of at least 5% in pre- and post-intervention measurements.

Secondary

MeasureTime frame
Secondary outcomes are not expected.

Countries

Brazil

Contacts

Public ContactEdvane De Domenico

Universidade Federal de São Paulo/Escola Paulista de Enfermagem

domenico.edvane@unifesp.br+55(11)50842793

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 6, 2026